Selective inhibition of SIRT2: A disputable therapeutic approach in cancer therapy

Area of Science:

• Molecular Biology
• Biochemistry
• Oncology

Background:

• Sirtuin 2 (SIRT2) is a protein deacetylase implicated in diverse cellular functions, including transcription, metabolism, and genome stability.
• SIRT2 dysregulation is linked to the pathogenesis and progression of diseases such as cancer and neurodegenerative disorders.
• Targeting SIRT2 activity with small molecule inhibitors presents a potential therapeutic strategy, especially for cancer treatment.

Purpose of the Study:

• To review the regulatory roles and molecular mechanisms of SIRT2 in cancer.
• To summarize evaluations of potential antitumor activities of SIRT2-selective inhibitors.
• To explore the development of novel SIRT2 inhibitors with high affinity and selectivity.

Main Methods:

• Review of existing literature on SIRT2 function in cancer.
• Analysis of in vitro and in vivo studies assessing SIRT2 inhibitor efficacy.
• Examination of molecular mechanisms underlying SIRT2's role in tumorigenesis.

Main Results:

• SIRT2 is a significant regulator in cancer development and progression.
• SIRT2 inhibitors demonstrate potential antitumor effects in preclinical models.
• Current research highlights the need for highly selective SIRT2 inhibitors.

Conclusions:

• Understanding SIRT2's role in tumorigenesis is crucial for developing targeted therapies.
• SIRT2 inhibitors represent a promising avenue for cancer treatment.
• Further research into developing potent and selective SIRT2 inhibitors is warranted.